Other names that will look familiar if one has bee
Post# of 30067
(Total Views: 594)
Posted On: 07/12/2019 11:41:44 PM
Other names that will look familiar if one has been following closely.
From The Todos Corporate Presentation
June 2019
Management Team
Dr. Herman Weiss, MD, MBA, FACOG – President & CEO
Former VP, Medical Affairs and Clinical Development of Juniper Pharmaceuticals Inc.
Former Global Medical Director of Women’s Health and Bone Health at Teva Pharmaceutical Industries.
Dr. Udi Zelig, PhD – CTO
Scientific founder of Todos Medical & Senior at Ben Gurion University
Former Chief Technology Officer at Crow Technologies
***Michael T. Ropacki, PHD - Chief Medical Advisor, LymPro for Alzheimer’s
SVP Clinical Development at MedAvante-ProPhase
Former Global Medical Affairs Leader, Head of Late-Stage Development at Janssen Alzheimer's
Immunotherapy
***Brian E. Harvey, MD, PHD - Chief Regulatory Advisor
Former Vice President of U.S Regulatory Strategy at Pfizer
Former Vice President of Regulatory Policy at Sanofi
Mr. David Ben Naim, MBA, CPA - CFO
Former CFO at Insuline Medical Inc (TASE – INSL), Crow Technologies (OTCQB – CRWTF), Ilex Medical
Limited (TASE), Microbot Medical (NASDAQ – MBOT) and Vonetize PLC (TASE – VNTZ).
Advisors:
***Gerald Commissiong: President & CEO of Amarantus Bioscience Holdings,
And from the Todos Board of Directors tab
***DR. COLIN BIER — DIRECTOR
Dr. Bier, currently serves as Managing Director of ABA BioResearch Inc. From September 2013 until 2018, he served as a Corporate Advisor of Amarantus Bioscience Holdings, Inc. He also served as a Senior Advisor of TVM V Life Science Ventures and NGN Capital. From November 2001 to June 15, 2002, Dr. Bier served as Chairman of the Board and Chief Executive Officer of Soligenix, Inc. From 1996 through 2008, Dr. Bier was a Director of Neurochem Inc. Dr. Bier serves as a Director of Lomir Biomedical Inc., a private company, of Mount Sinai Hospital Montreal, and of Receptagen, a publicly traded company. He has published more than twenty-five scientific articles in his field in peer-reviewed journals.
Dr. Bier received his Ph.D. in Experimental Pathology from Colorado State University in 1978 and then pursued additional training in experimental pathology and toxicology a Medical Research Council Postdoctoral Fellow and the Dr. Douglas James Fellow in the Department of Pathology, McGill University. He received his M.Sc. from Long Island University in 1974, and his B.A. from Sir George Williams University in 1967.
And now PAULA TRZEPACZ, MD.
Aloha
From The Todos Corporate Presentation
June 2019
Management Team
Dr. Herman Weiss, MD, MBA, FACOG – President & CEO
Former VP, Medical Affairs and Clinical Development of Juniper Pharmaceuticals Inc.
Former Global Medical Director of Women’s Health and Bone Health at Teva Pharmaceutical Industries.
Dr. Udi Zelig, PhD – CTO
Scientific founder of Todos Medical & Senior at Ben Gurion University
Former Chief Technology Officer at Crow Technologies
***Michael T. Ropacki, PHD - Chief Medical Advisor, LymPro for Alzheimer’s
SVP Clinical Development at MedAvante-ProPhase
Former Global Medical Affairs Leader, Head of Late-Stage Development at Janssen Alzheimer's
Immunotherapy
***Brian E. Harvey, MD, PHD - Chief Regulatory Advisor
Former Vice President of U.S Regulatory Strategy at Pfizer
Former Vice President of Regulatory Policy at Sanofi
Mr. David Ben Naim, MBA, CPA - CFO
Former CFO at Insuline Medical Inc (TASE – INSL), Crow Technologies (OTCQB – CRWTF), Ilex Medical
Limited (TASE), Microbot Medical (NASDAQ – MBOT) and Vonetize PLC (TASE – VNTZ).
Advisors:
***Gerald Commissiong: President & CEO of Amarantus Bioscience Holdings,
And from the Todos Board of Directors tab
***DR. COLIN BIER — DIRECTOR
Dr. Bier, currently serves as Managing Director of ABA BioResearch Inc. From September 2013 until 2018, he served as a Corporate Advisor of Amarantus Bioscience Holdings, Inc. He also served as a Senior Advisor of TVM V Life Science Ventures and NGN Capital. From November 2001 to June 15, 2002, Dr. Bier served as Chairman of the Board and Chief Executive Officer of Soligenix, Inc. From 1996 through 2008, Dr. Bier was a Director of Neurochem Inc. Dr. Bier serves as a Director of Lomir Biomedical Inc., a private company, of Mount Sinai Hospital Montreal, and of Receptagen, a publicly traded company. He has published more than twenty-five scientific articles in his field in peer-reviewed journals.
Dr. Bier received his Ph.D. in Experimental Pathology from Colorado State University in 1978 and then pursued additional training in experimental pathology and toxicology a Medical Research Council Postdoctoral Fellow and the Dr. Douglas James Fellow in the Department of Pathology, McGill University. He received his M.Sc. from Long Island University in 1974, and his B.A. from Sir George Williams University in 1967.
And now PAULA TRZEPACZ, MD.
Aloha
(2)
(0)